Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Trial Profile

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Dacarbazine
  • Indications Leiomyosarcoma; Liposarcoma; Myxoid liposarcoma; Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd; Eisai Inc
  • Most Recent Events

    • 01 Apr 2021 Results of an exploratory molecular analysis published in the Clinical Cancer Research
    • 24 Jun 2020 Results assessing the molecular profile of LMS tumors from North American study sites assessing to identify potential predictive molecular factors for treatment with eribulin, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
    • 08 May 2019 Results of a sub-group analysis assessing eribulin versus dacarbazine in patients with leiomyosarcoma (n=309) published in the British Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top